NetworkNewsWire Editorial
Coverage: The discovery of the human
body’s endocannabinoid system in the early 1990s led to a surge of
new drug development activity to address multiple maladies and
identify new ways to treat serious diseases. The pharma industry’s
predominant focus has been on the most recognized and
easiest-to-isolate plant-sourced cannabinoids THC
(tetrahydrocannabinol) and CBD (cannabidiol). Despite their
potential therapeutic efficacy, plant-sourced cannabinoid therapies
have complex development limitations that impede effective use.
Beyond economic constraints on production, inherent problems exist
in ensuring the quality, purity and consistency requisite for
serious pharmaceutical drug development. But InMed
Pharmaceuticals, Inc. (CSE: IN) (OTCQB: IMLFF) (IMLFF
Profile) has initiated a scientific paradigm shift in
discovering potential breakthrough cannabinoid-based therapies that
advances far beyond basic cannabinoid production and the
over-the-counter sales of oils and elixirs. The company’s
proprietary biosynthesis process sets it apart from the operations
of companies like Isodiol International, Inc. (OTCQB:
ISOLF) (ISOL: CNX), as well as from other biotechs and
growers in the cannabis industry who rely on the supply of leading
cultivators like Canopy Growth Corp. (TSX: WEED) (OTC:
TWMJF), Aurora Cannabis, Inc. (TSX: ACB) (OTCQB: ACBFF)
and Aphria, Inc. (TSX: APH) (OTC: APHQF).
The human endocannabinoid system is one of the most important
physiologic systems involved in general well-being. The human body
naturally produces endocannabinoids, which bind to cannabinoid
receptors present in the body where they act as chemical messengers
between cells, tissues and organs. This innate biological system
has been found to interact with the 90+ cannabinoids identified in
the cannabis plant, leading to a wide range of pharmacological
effects related to pain, inflammation, neurotransmission, stress,
metabolism, appetite and several other body functions.
InMed
Pharmaceuticals, Inc. (CSE: IN) (OTCQB: IMLFF) has a robust,
proprietary biosynthesis process to manufacture
pharmaceutical-grade (greater than 95% purity) cannabinoids using a
cost-effective, laboratory-based process.
Biosynthesis is the preparation of biological molecules using
catalysts derived from natural substances, which are then converted
into other compounds. As an example, millions of diabetics use
insulin produced via biosynthesis. InMed’s proprietary biosynthetic
process produces cannabinoids that are identical to naturally
occurring compounds and is transformative in ensuring the
pharmaceutical standards for therapeutic cannabinoids. This novel
breakthrough gives InMed the ability to bio-identically manufacture
every cannabinoid compound found in nature and the ability to
consistently, reliably and accurately test the compounds’
therapeutic efficacy and safety.
InMed employs a proprietary bioinformatics drug and
disease-targeting tool in conjunction with its biosynthesis
process. Bioinformatics is a high-efficiency, computer-assisted
approach to predicting the therapeutic potential and medicinal
properties of individual cannabinoids against particular medical
conditions. InMed’s approach applies comprehensive algorithms to
combine data from various bioinformatics databases with its
proprietary cannabinoid database.
These systems give the company significant competitive
advantage. To protect this invaluable asset, InMed has filed a
provisional patent for the biosynthesis of cannabinoids (http://nnw.fm/RPTj0), using the process as a base to
expand its pipeline of drug candidates. InMed’s current pipeline
includes INM-750 to treat epidermolysis bullosa, a rare disease
characterized by extremely fragile skin, with potential global
market revenues estimated around US$1 billion per year; INM-085, in
development to treat glaucoma, with global market potential of more
than US$5 billion; and INM-405, which targets the US$36
billion-plus global market for pain therapy.
Study results published earlier this year by InMed in the
European Journal of Pain (http://nnw.fm/8RbQF) highlighted the topical
application of certain cannabinoids to successfully treat
peripheral pain. Study results (http://nnw.fm/4nCmZ) suggest InMed’s approach may
prove valuable in the treatment of severe craniofacial muscle pain
disorders and there’s reason to believe similar benefits for
treating osteoarthritis may been seen.
In the latest market report published by Credence Research, Inc.
(http://nnw.fm/pDKs0), the osteoarthritis
treatment market was valued at US$5 billion in 2015. Despite
medical advances, there remain significant unmet medical needs in
treating osteoarthritis due to the absence of effective therapies
for the chronic disease. Currently available treatment options
don’t provide adequate pain relief, especially in the late stages
of osteoarthritis, which has led to increased opioid abuse. As
such, there is a real need to find non-addictive alternatives with
limited side effects to treat chronic and severe pain, and InMed’s
comprehensive pharmaceutical approach to cannabinoid drug
development may prove to be the solution.
Many other companies are pursuing medicinal cannabinoids, mostly
CBD, through horticultural cultivation. The process of planting,
growing, harvesting, extracting and purifying the product is
costly, inexact, inconsistent and unreliable. A recent study
published in JAMA (http://nnw.fm/f9FAa) revealed that nearly 70% of CBD
extracts from marijuana sold online are mislabeled, some had extra
CBD, some less, and some contained hidden cannabinoids. Blind
testing found that only about 31 percent of the extracts tested
contained the amount of CBD listed on the label (within a 10%
allowed variance).
InMed’s ability to consistently manufacture pharmaceutical-grade
cannabinoids may prove to be a significant advantage over
traditional cannabis growers.
Companies developing medicinal cannabinoids through traditional
horticultural methods include Canopy Growth (TSX: WEED)
(OTC: TWMJF), a diversified Canadian cannabis company
offering distinct brands and curated cannabis varieties in dried,
oil and capsule forms. Through its 665,000 square feet of licensed
production, over 500,000 square feet of which is good manufacturing
practice (GMP) certified. Canopy Growth and its affiliates plan to
develop a production platform that would represent 3.2 million
square feet of indoor and greenhouse production capacity, all
operated with leading edge production, quality assurance
procedures, value-added post processing, research and testing.
Canopy Growth has established partnerships with recognized sector
names in Canada and abroad, with interests and operations spanning
seven countries and four continents. The company is dedicated to
educating healthcare practitioners, providing consistent access to
high-quality cannabis products, conducting robust clinical
research, and furthering the public's understanding of
cannabis.
Through its wholly-owned subsidiary, Aurora Cannabis Enterprises
Inc., Aurora Cannabis (TSX: ACB) (OTCQB: ACBFF) is
a Canadian licensed producer of horticulturally grown medical
cannabis. The company operates a 55,200-square-foot production
facility in Alberta and a second 40,000-square-foot production
facility in Quebec. The company is constructing an
800,000-square-foot production facility at the Edmonton
International Airport, as well as a fourth facility in Lachute,
Quebec, through its wholly-owned subsidiary Aurora Larssen Projects
Ltd. Aurora holds about 19 percent of the issued shares in an
extraction technology company, Radient Technologies Inc., and is in
the process of completing an investment for up to 50.1 percent of
Hempco Food and Fiber. Aurora also holds a 22.9 percent stake in
Cann Group Limited, the first Australian company licensed to
cultivate and research medical cannabis. Aurora owns Pedanios, a
wholesale importer, exporter and distributor of medical cannabis in
the EU.
One of Canada’s lowest-cost horticultural producers,
Aphria (TSX: APH) (OTC: APHQF), cultivates,
supplies and sells medical cannabis. Located in Leamington,
Ontario, Aphria is powered by sunlight, allowing for some of the
most natural growing conditions available. Aphria is committed to
providing pharma-grade medical cannabis for superior patient care
while balancing patient economics and returns to shareholders.
Aphria’s medicinal cannabis is 100 percent greenhouse grown in
natural sunlight and offers a patient care team to assist customers
purchasing its THC and CBD products.
Isodiol International (CSE: ISOL) (OTC: ISOLF) (FSE:
LB6A.F) is a market leader in pharmaceutical- and
nutraceutical-grade phytochemical (plant-based) compounds,
specializing in the manufacturing and development of phytoceutical
consumer products. Isodiol is one of the world’s largest sources
for phytocannabinoids and offers high-quality, bioactive products
from seed to finished product. Isodiol is a pioneer in the cannabis
industry for the commercialization of 99 percent-plus pure,
bioactive pharmaceutical grade cannabinoids, micro-encapsulations
and nanotechnology for high-quality consumable and topical skin
care products. Isodiol’s growth strategy includes the development
of over-the-counter and pharmaceutical drugs, expanding its
phytoceutical portfolio and aggressively continuing its
international expansion into Latin America, Asia, and Europe.
The discovery of the human endocannabinoid system and its
interaction with cannabinoids to produce pharmacological modulation
for pain, inflammation and other ailments may provide the long
sought-after solutions to effectively treat pain inherent with
osteoarthritis and other chronic and severe illnesses. There’s
immense promise that pharmacological cannabinoids may soon provide
relief for suffering patients and there’s an economic bonanza
waiting for companies like InMed that aim to bring these
blockbuster cannabis-based drugs to market.
For more information on InMed Pharmaceuticals, please visit:
InMed
Pharmaceuticals, Inc. (CSE: IN) (OTCQB: IMLFF)
About NetworkNewsWire
NetworkNewsWire (NNW) is an information service that provides
(1) access to our news aggregation and syndication servers, (2)
NetworkNewsBreaks that summarize corporate news and
information, (3) enhanced press release services, (4) social media
distribution and optimization services, and (5) a full array of
corporate communication solutions. As a multifaceted financial news
and content distribution company with an extensive team of
contributing journalists and writers, NNW is uniquely positioned to
best serve private and public companies that desire to reach a wide
audience of investors, consumers, journalists and the general
public. NNW has an ever-growing distribution network of more than
5,000 key syndication outlets across the country. By cutting
through the overload of information in today’s market, NNW brings
its clients unparalleled visibility, recognition and brand
awareness. NNW is where news, content and information converge.
NetworkNewsWire (NNW)
New York, New York
www.NetworkNewsWire.com
212.418.1217 Office
Editor@NetworkNewsWire.com
Please see full terms of use and disclaimers on the
NetworkNewsWire website applicable to all content provided by NNW,
wherever published or re-published: http://NNW.fm/Disclaimer
DISCLAIMER: NetworkNewsWire (NNW) is the source of the Article
and content set forth above. References to any issuer other than
the profiled issuer are intended solely to identify industry
participants and do not constitute an endorsement of any issuer and
do not constitute a comparison to the profiled issuer. The
commentary, views and opinions expressed in this release by NNW are
solely those of NNW. Readers of this Article and content agree that
they cannot and will not seek to hold liable NNW for any investment
decisions by their readers or subscribers. NNW are a news
dissemination and financial marketing solutions provider and are
NOT registered broker-dealers/analysts/investment advisers, hold no
investment licenses and may NOT sell, offer to sell or offer to buy
any security.
The Article and content related to the profiled company
represent the personal and subjective views of the Author, and are
subject to change at any time without notice. The information
provided in the Article and the content has been obtained from
sources which the Author believes to be reliable. However, the
Author has not independently verified or otherwise investigated all
such information. None of the Author, NNW, or any of their
respective affiliates, guarantee the accuracy or completeness of
any such information. This Article and content are not, and should
not be regarded as investment advice or as a recommendation
regarding any particular security or course of action; readers are
strongly urged to speak with their own investment advisor and
review all of the profiled issuer’s filings made with the
Securities and Exchange Commission before making any investment
decisions and should understand the risks associated with an
investment in the profiled issuer’s securities, including, but not
limited to, the complete loss of your investment.
NNW HOLDS NO SHARES OF ANY COMPANY NAMED IN THIS RELEASE.
This release contains “forward-looking statements” within the
meaning of Section 27A of the Securities Act of 1933, as amended,
and Section 21E the Securities Exchange Act of 1934, as amended and
such forward-looking statements are made pursuant to the safe
harbor provisions of the Private Securities Litigation Reform Act
of 1995. “Forward-looking statements” describe future expectations,
plans, results, or strategies and are generally preceded by words
such as “may”, “future”, “plan” or “planned”, “will” or “should”,
“expected,” “anticipates”, “draft”, “eventually” or “projected”.
You are cautioned that such statements are subject to a multitude
of risks and uncertainties that could cause future circumstances,
events, or results to differ materially from those projected in the
forward-looking statements, including the risks that actual results
may differ materially from those projected in the forward-looking
statements as a result of various factors, and other risks
identified in a company’s annual report on Form 10-K or 10-KSB and
other filings made by such company with the Securities and Exchange
Commission. You should consider these factors in evaluating the
forward-looking statements included herein, and not place undue
reliance on such statements. The forward-looking statements in this
release are made as of the date hereof and NNW undertake no
obligation to update such statements.
Source:
NetworkNewsWire
Contact:
NetworkNewsWire (NNW)
New York, New York
www.NetworkNewsWire.com
212.418.1217 Office
Editor@NetworkNewsWire.com
Isodiol (CSE:ISOL)
Historical Stock Chart
From Nov 2024 to Dec 2024
Isodiol (CSE:ISOL)
Historical Stock Chart
From Dec 2023 to Dec 2024
